[ET Net News Agency, 21 December 2023] Morgan Stanley lowered its target price for
Sinopharm (01099) to HKD29 from HKD30 and maintained its "overweight" rating.
The research house said based on 3Q23 reporting and recent monthly trend, it trims
2023-2030 earnings forecasts by ~2% on lower device segment sales and gross margins. (RC)